

Michael E Weinblatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103206/publications.pdf>

Version: 2024-02-01

170
papers

19,815
citations

23879

60
h-index

11946

139
g-index

185
all docs

185
docs citations

185
times ranked

12555
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity. <i>Rheumatology and Therapy</i> , 2022, 9, 637-647. | 1.1 | 4 |
| 2 | Screening for preclinical parenchymal lung disease in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 3234-3245. | 0.9 | 14 |
| 3 | Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 391-409. | 1.1 | 3 |
| 4 | Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480. | 1.5 | 12 |
| 5 | American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e1-e12. | 2.9 | 201 |
| 6 | Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). <i>Journal of Rheumatology</i> , 2021, 48, 767-774. | 1.0 | 33 |
| 7 | Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 1259-1271. | 1.0 | 11 |
| 8 | Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. <i>JAMA Dermatology</i> , 2021, 157, 735. | 2.0 | 6 |
| 9 | 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939. | 1.5 | 466 |
| 10 | 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123. | 2.9 | 339 |
| 11 | Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study. <i>ACR Open Rheumatology</i> , 2021, 3, 522-530. | 0.9 | 4 |
| 12 | Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. <i>Blood Advances</i> , 2021, 5, 3445-3456. | 2.5 | 22 |
| 13 | Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. <i>Arthritis Research and Therapy</i> , 2021, 23, 1. | 1.6 | 41 |
| 14 | Dr. Kremer et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210992. | 1.0 | 0 |
| 15 | Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change. <i>Journal of Rheumatology</i> , 2020, 47, 333-340. | 1.0 | 5 |
| 16 | Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. <i>Arthritis Care and Research</i> , 2020, 72, 176-183. | 1.5 | 11 |
| 17 | Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93. | 0.5 | 63 |
| 18 | Georgia Abortion Law and Our Commitment to Patients. <i>Arthritis and Rheumatology</i> , 2020, 72, 377-378. | 2.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1216-1225. | 1.6 | 18 |
| 20 | American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2020, 72, e1-e12. | 2.9 | 64 |
| 21 | Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188. | 1.6 | 2 |
| 22 | The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200692. | 1.0 | 9 |
| 23 | Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. <i>ACR Open Rheumatology</i> , 2020, 2, 357-361. | 0.9 | 43 |
| 24 | Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096. | 1.8 | 3 |
| 25 | Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2017. | 1.0 | 0 |
| 26 | American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1241-1251. | 2.9 | 142 |
| 27 | Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. <i>Clinical Rheumatology</i> , 2019, 38, 3401-3412. | 1.0 | 11 |
| 28 | The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 1.0 | 5 |
| 29 | Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). <i>Rheumatology and Therapy</i> , 2019, 6, 559-571. | 1.1 | 15 |
| 30 | Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1042-1055. | 2.9 | 135 |
| 31 | Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis. <i>Practical Laboratory Medicine</i> , 2019, 16, e00122. | 0.6 | 2 |
| 32 | Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients aÅUS Observational Cohort. <i>Clinical Therapeutics</i> , 2019, 41, 1057-1065.e3. | 1.1 | 0 |
| 33 | Rheumatoid Nodule Formation in the Kidney: A Diagnosis of Exclusion and a Rare Manifestation of Rheumatoid Arthritis Involving the Kidney. <i>Kidney International Reports</i> , 2019, 4, 745-748. | 0.4 | 2 |
| 34 | Prevalence and predictors for sustained remission in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0214981. | 1.1 | 12 |
| 35 | Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061. | 0.5 | 25 |
| 36 | Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 3. | 0.6 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1285-1286. | 0.5 | 5 |
| 38 | Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients With Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 4-15. | 0.9 | 5 |
| 39 | AB0373â€¦A COMPARATIVE EFFECTIVENESS STUDY OF ABATACEPT AND TNFI AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING REAL-WORLD DATA. , 2019, , . | | 0 |
| 40 | SAT0072â€¦EVALUATION OF RHEUMATOID ARTHRITIS TREATMENTS AND JOINT OUTCOMES IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. , 2019, , . | | 0 |
| 41 | FRI0171â€¦CLINICAL RESPONSES IN PATIENTS WITH INADEQUATE RESPONSE TO BDMARDS UPON TREATMENT WITH UPADACITINIB. , 2019, , . | | 3 |
| 42 | THU0065â€¦VALIDATION OF THE ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR PREDICTING RISK OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , . | | 0 |
| 43 | SAT0162â€¦A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , . | | 0 |
| 44 | THU0102â€¦PATIENT DISEASE TRAJECTORIES IN BARICITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE. , 2019, , . | | 0 |
| 45 | Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach. <i>ACR Open Rheumatology</i> , 2019, 1, 552-559. | 0.9 | 7 |
| 46 | The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study. <i>ACR Open Rheumatology</i> , 2019, 1, 620-626. | 0.9 | 9 |
| 47 | Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883. | 0.9 | 16 |
| 48 | Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878. | 0.5 | 36 |
| 49 | Impact of Changes in Inflammation on Estimated Tenâ€¥ear Cardiovascular Risk in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1392-1398. | 2.9 | 13 |
| 50 | Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1419-1428. | 2.9 | 21 |
| 51 | Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort. <i>Advances in Therapy</i> , 2018, 35, 232-242. | 1.3 | 9 |
| 52 | Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 203-214. | 1.1 | 10 |
| 53 | Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 832-840. | 2.9 | 103 |
| 54 | Mavrimumab, a Fully Human Granulocyteâ€¥Macrophage Colonyâ€¥Stimulating Factor Receptor Î± Monoclonal Antibody. <i>Arthritis and Rheumatology</i> , 2018, 70, 679-689. | 2.9 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. <i>Arthritis and Rheumatology</i> , 2018, 70, 1331-1342. | 2.9 | 15 |
| 56 | Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e4-e4. | 0.5 | 7 |
| 57 | Phase <i>III</i> Randomized Study of <i>SB</i> 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 40-48. | 2.9 | 104 |
| 58 | A Randomized Phase <i>IIb</i> Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 49-59. | 2.9 | 76 |
| 59 | Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study. <i>Rheumatology</i> , 2018, 57, . | 0.9 | 0 |
| 60 | Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013. | 1.1 | 9 |
| 61 | Phase <i>II</i> Study of <i>ABT</i> -122, a Tumor Necrosis Factor and Interleukin-17A Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2018, 70, 1778-1789. | 2.9 | 77 |
| 62 | <i>ABT</i> -122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2018, 70, 1710-1720. | 2.9 | 55 |
| 63 | Dual inhibition of tumour necrosis factor and interleukin-17A with <i>ABT</i> -122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. <i>Rheumatology</i> , 2018, 57, 1972-1981. | 0.9 | 30 |
| 64 | Methotrexate: who would have predicted its importance in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2018, 20, 103. | 1.6 | 18 |
| 65 | Targeted therapies for psoriatic arthritis: an update for the dermatologist. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 173-181. | 1.6 | 4 |
| 66 | Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease. <i>Blood</i> , 2018, 132, 3716-3716. | 0.6 | 0 |
| 67 | Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. <i>Arthritis Care and Research</i> , 2017, 69, 1920-1925. | 1.5 | 49 |
| 68 | A randomised phase <i>IIb</i> study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1020-1030. | 0.5 | 117 |
| 69 | Fibromyalgia and the Prediction of Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1871-1877. | 1.5 | 12 |
| 70 | Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 652-662. | 13.9 | 643 |
| 71 | Antimelanoma Differentiation-associated Gene 5 Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 850-851. | 1.0 | 2 |
| 72 | Refractory Syndrome of Inappropriate Secretion of Antidiuretic Hormone in Systemic Lupus Erythematosus-associated Hypophysitis. <i>Journal of Rheumatology</i> , 2017, 44, 541-542. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1853-1861. | 0.5 | 83 |
| 74 | Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. <i>BMC Medical Research Methodology</i> , 2017, 17, 59. | 1.4 | 7 |
| 75 | Validity of the Nursesâ€™ health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 234. | 0.8 | 9 |
| 76 | Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. <i>Arthritis Research and Therapy</i> , 2017, 19, 130. | 1.6 | 2 |
| 77 | A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948. | 2.9 | 32 |
| 78 | Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727. | 2.9 | 24 |
| 79 | Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. <i>RMD Open</i> , 2016, 2, e000210. | 1.8 | 3 |
| 80 | Patientâ€™Reported Outcomes From a Twoâ€™Year Headâ€™toâ€™Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 907-913. | 1.5 | 24 |
| 81 | Efficacy and Safety of ABTâ€™494, a Selective JAKâ€™ Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2016, 68, 2857-2866. | 2.9 | 172 |
| 82 | Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460. | 5.8 | 73 |
| 83 | Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. <i>Rheumatology</i> , 2016, 55, 640-648. | 0.9 | 29 |
| 84 | Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 709-714. | 0.5 | 134 |
| 85 | Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Weekâ€™12 Efficacy and Safety Results of the Openâ€™Label Longâ€™Term Extension of a Phase III, Doubleâ€™Blind, Randomized, Placeboâ€™Controlled Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1627-1636. | 1.5 | 13 |
| 86 | Editorial: The Vital Role of Randomized Controlled Trials in <i>Arthritis & Rheumatology</i>. <i>Arthritis and Rheumatology</i> , 2015, 67, 2555-2556. | 2.9 | 1 |
| 87 | Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. <i>Arthritis Research and Therapy</i> , 2015, 17, 325. | 1.6 | 16 |
| 88 | Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 343. | 1.6 | 13 |
| 89 | The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderateâ€™toâ€™Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Doubleâ€™Blind, Placebo/Activeâ€™Controlled, Doseâ€™Ranging Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 2591-2600. | 2.9 | 86 |
| 90 | The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2015, 54, 2076-2084. | 0.9 | 74 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis. <i>Journal of the American Heart Association</i> , 2015, 4, . | 1.6 | 102 |
| 92 | OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2123-2129. | 0.5 | 39 |
| 93 | Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173. | 1.6 | 58 |
| 94 | Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1567-1570. | 0.5 | 31 |
| 95 | An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. <i>Arthritis Research and Therapy</i> , 2015, 17, 83. | 1.6 | 13 |
| 96 | Modular Analysis of Peripheral Blood Gene Expression in Rheumatoid Arthritis Captures Reproducible Gene Expression Changes in Tumor Necrosis Factor Responders. <i>Arthritis and Rheumatology</i> , 2015, 67, 344-351. | 2.9 | 42 |
| 97 | Clinical characteristics of RA patients with secondary SS and association with joint damage. <i>Rheumatology</i> , 2015, 54, 816-820. | 0.9 | 41 |
| 98 | Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis. <i>Chest</i> , 2014, 146, 41-50. | 0.4 | 78 |
| 99 | Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis. <i>Journal of Rheumatology</i> , 2014, 41, 2370-2378. | 1.0 | 9 |
| 100 | Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1â€¦.year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2152-2159. | 0.5 | 29 |
| 101 | Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 3255-3264. | 2.9 | 96 |
| 102 | Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) Tj ETQq0 0 0 rgBT /Overlock 10 Tf therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1616-1625. | 0.5 | 135 |
| 103 | The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf | 1.0 | 14 |
| 104 | Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760. | 0.5 | 11 |
| 105 | The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial. <i>Journal of Rheumatology</i> , 2014, 41, 1067-1076. | 1.0 | 14 |
| 106 | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-1± Antagonist. <i>Journal of Rheumatology</i> , 2014, 41, 2120-2128. | 1.0 | 57 |
| 107 | Serum 14-3-3± is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113. | 1.0 | 72 |
| 108 | Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 86-94. | 0.5 | 256 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Rheumatoid arthritis quality measures and radiographic progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 9-13. | 1.6 | 6 |
| 110 | 86.â€fHead-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in Rheumatoid Arthritis: Blinded Two-Year Results from the Ample Study. <i>Rheumatology</i> , 2014, 53, i88-i88. | 0.9 | 0 |
| 111 | Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1445-1452. | 0.5 | 149 |
| 112 | Headâ€toâ€head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. <i>Arthritis and Rheumatism</i> , 2013, 65, 28-38. | 6.7 | 225 |
| 113 | Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. <i>Journal of Rheumatology</i> , 2013, 40, 787-797. | 1.0 | 112 |
| 114 | Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 381-389. | 0.5 | 90 |
| 115 | Tocilizumab as monotherapy or in combination with nonbiologic diseaseâ€modifying antirheumatic drugs: Twentyâ€fourâ€week results of an openâ€label, clinical practice study. <i>Arthritis Care and Research</i> , 2013, 65, 362-371. | 1.5 | 56 |
| 116 | Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. <i>Journal of Rheumatology</i> , 2013, 40, 369-378. | 1.0 | 42 |
| 117 | Methotrexate in rheumatoid arthritis: a quarter century of development. <i>Transactions of the American Clinical and Climatological Association</i> , 2013, 124, 16-25. | 0.9 | 117 |
| 118 | Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214. | 0.9 | 115 |
| 119 | Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 373-382. | 1.5 | 58 |
| 120 | A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 846-854. | 1.0 | 108 |
| 121 | An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A threeâ€month randomized, placeboâ€controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. <i>Arthritis and Rheumatism</i> , 2011, 63, 337-345. | 6.7 | 190 |
| 122 | Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 855-862. | 1.0 | 25 |
| 123 | Factors Associated with Radiographic Progression in Patients with Rheumatoid Arthritis Who Were Treated with Methotrexate. <i>Journal of Rheumatology</i> , 2011, 38, 242-246. | 1.0 | 23 |
| 124 | An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2010, 363, 1303-1312. | 13.9 | 369 |
| 125 | Case 13-2009. <i>New England Journal of Medicine</i> , 2009, 360, 1770-1779. | 13.9 | 9 |
| 126 | Methotrexate: The Foundation of Rheumatoid Arthritis Therapy. , 2009, , 307-314. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug-controlled study. <i>Arthritis and Rheumatism</i> , 2008, 58, 1921-1930. | 6.7 | 71 |
| 128 | Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008, 58, 3309-3318. | 6.7 | 313 |
| 129 | Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. <i>Arthritis Research and Therapy</i> , 2008, 10, R95. | 1.6 | 57 |
| 130 | Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1737-44. | 1.0 | 27 |
| 131 | Questions and answers in 2008 about biologics in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1878-81. | 1.0 | 0 |
| 132 | RAPID: rheumatoid arthritis. <i>Journal of Family Practice</i> , 2007, 56, S1-7; quiz S8. | 0.2 | 6 |
| 133 | The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. <i>Arthritis Research and Therapy</i> , 2006, 8, R57. | 1.6 | 22 |
| 134 | Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 228-234. | 0.5 | 261 |
| 135 | Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. <i>Journal of Rheumatology</i> , 2006, 33, 659-64. | 1.0 | 34 |
| 136 | Granulomatous lung disease occurring during etanercept treatment. <i>Arthritis and Rheumatism</i> , 2005, 53, 618-620. | 6.7 | 70 |
| 137 | Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. <i>Arthritis and Rheumatism</i> , 2005, 53, 872-878. | 6.7 | 49 |
| 138 | Rheumatoid arthritis: more aggressive approach improves outlook.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 409-413. | 0.6 | 14 |
| 139 | Adalimumab, a fully human anti-tumor necrosis factor γ monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 35-45. | 6.7 | 1,612 |
| 140 | Infections and anti-tumor necrosis factor γ therapy. <i>Arthritis and Rheumatism</i> , 2003, 48, 3013-3022. | 6.7 | 285 |
| 141 | The best of times, the worst of times: <i>Rheumatology</i> 2001. <i>Arthritis and Rheumatism</i> , 2002, 46, 567-573. | 6.7 | 9 |
| 142 | How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002, 47, 215-218. | 6.7 | 132 |
| 143 | Etanercept in the treatment of adult patients with Still's disease. <i>Arthritis and Rheumatism</i> , 2002, 46, 1171-1176. | 6.7 | 179 |
| 144 | Serious liver disease in a patient receiving methotrexate and leflunomide. <i>Arthritis and Rheumatism</i> , 2000, 43, 2609-2611. | 6.7 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1322-1328. | 6.7 | 248 |
| 146 | A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. <i>New England Journal of Medicine</i> , 1999, 340, 253-259. | 13.9 | 2,044 |
| 147 | Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. A multicenter study with literature review. <i>Arthritis and Rheumatism</i> , 1997, 40, 1829-1837. | 6.7 | 279 |
| 148 | Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 177-178. | 6.7 | 3 |
| 149 | N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: A pilot study. <i>Arthritis and Rheumatism</i> , 1996, 39, 1021-1026. | 6.7 | 15 |
| 150 | Synovial tissue response to treatment with campath-1h. <i>Arthritis and Rheumatism</i> , 1995, 38, 254-258. | 6.7 | 50 |
| 151 | American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 727-735. | 6.7 | 2,531 |
| 152 | Methotrexate for Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1994, 37, 316-328. | 6.7 | 594 |
| 153 | Lack of a renalâ€œprotective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin a. results of a randomized, placeboâ€œcontrolled trial. <i>Arthritis and Rheumatism</i> , 1994, 37, 1321-1325. | 6.7 | 8 |
| 154 | Methotrexate in rheumatoid arthritis. a five-year prospective multicenter study. <i>Arthritis and Rheumatism</i> , 1994, 37, 1492-1498. | 6.7 | 216 |
| 155 | Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 329-335. | 6.7 | 187 |
| 156 | The effects of drug therapy on radiographic progression of rheumatoid arthritis. results of a 36-week randomized trial comparing methotrexate and auranofin. <i>Arthritis and Rheumatism</i> , 1993, 36, 613-619. | 6.7 | 100 |
| 157 | The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 1993, 36, 729-740. | 6.7 | 1,388 |
| 158 | Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 129-137. | 6.7 | 227 |
| 159 | Acute and chronic suppression of leukotriene B4 synthesis EX vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. <i>Arthritis and Rheumatism</i> , 1992, 35, 376-384. | 6.7 | 99 |
| 160 | Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 330-338. | 6.7 | 126 |
| 161 | Inhibition of Leukotriene B ₄ synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. <i>Arthritis and Rheumatism</i> , 1990, 33, 1149-1155. | 6.7 | 63 |
| 162 | Treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1989, 2, A23-A32. | 6.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. <i>Arthritis and Rheumatism</i> , 1989, 32, 1592-1596. | 6.7 | 85 |
| 164 | Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 167-175. | 6.7 | 235 |
| 165 | Cyclosporin A Treatment of Refractory Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1987, 30, 11-17. | 6.7 | 134 |
| 166 | Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1987, 30, 988-997. | 6.7 | 207 |
| 167 | Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 420-424. | 2.3 | 7 |
| 168 | Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 1985, 312, 818-822. | 13.9 | 833 |
| 169 | Chronic Monocytic Arthritis. <i>Arthritis and Rheumatism</i> , 1983, 26, 674-677. | 6.7 | 3 |
| 170 | Rheumatoid factor detection by nephelometry. <i>Arthritis and Rheumatism</i> , 1980, 23, 777-779. | 6.7 | 21 |